Oppenheimer upgrades Cypress Bioscience (CYPB 6.29) to Outperform from Perform with a $9 tgt saying they believe it is too early to draw definitive conclusions about Savella's long term trajectory from weekly scrips trends. Additionally the firm says, despite potential impact reimbursement issues for FMS drugs could have on Savella's NT growth, they believe access could improve over time, enabling sales to reach $230M by 2013